Aptevo Reports Reduced Infusion Reactions With Refined Mipletamig Dosing in AML Trial

PUBT · 1d ago
Aptevo Reports Reduced Infusion Reactions With Refined Mipletamig Dosing in AML Trial
  • Aptevo Therapeutics reported substantially fewer infusion-related reactions with mipletamig following initial dosing refinements in its ongoing RAINIER study.
  • The trial combines mipletamig with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients unfit for intensive chemotherapy.
  • The tolerability improvements do not establish better efficacy or longer treatment persistence.
  • Study completion is expected by year-end 2026, with regulatory discussions and Phase 2 initiation planned for 2027.
  • Mipletamig data will be presented at the American Society of Hematology annual meeting in New Orleans, December 12-15, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptevo Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202611050830ACCESSWRNAPR_____1247122) on November 05, 2026, and is solely responsible for the information contained therein.